Repligen (RGEN) Downgraded by Zacks Investment Research

Repligen (NASDAQ:RGEN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday.

According to Zacks, “Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. “

RGEN has been the topic of several other research reports. BidaskClub lowered Repligen from a “hold” rating to a “sell” rating in a report on Friday, January 19th. TheStreet raised Repligen from a “c” rating to a “b-” rating in a report on Tuesday, March 13th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $44.25.

Repligen opened at $42.06 on Friday, MarketBeat.com reports. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 60.96, a price-to-earnings-growth ratio of 2.78 and a beta of 0.83. The company has a debt-to-equity ratio of 0.17, a current ratio of 12.22 and a quick ratio of 10.25. Repligen has a 1 year low of $41.65 and a 1 year high of $42.10.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.02. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $43.88 million. Repligen had a return on equity of 6.06% and a net margin of 18.48%. Repligen’s revenue was up 46.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.15 earnings per share. sell-side analysts anticipate that Repligen will post 0.71 EPS for the current year.

In related news, Director Karen A. Dawes sold 20,000 shares of the stock in a transaction on Friday, May 11th. The stock was sold at an average price of $41.80, for a total transaction of $836,000.00. Following the sale, the director now owns 114,957 shares of the company’s stock, valued at $4,805,202.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 4,696 shares of the stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $36.16, for a total value of $169,807.36. Following the sale, the director now directly owns 9,700 shares in the company, valued at approximately $350,752. The disclosure for this sale can be found here. Insiders sold 171,196 shares of company stock worth $6,954,517 in the last three months. 1.40% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. boosted its stake in shares of Repligen by 38.9% during the first quarter. Victory Capital Management Inc. now owns 5,755 shares of the biotechnology company’s stock valued at $208,000 after acquiring an additional 1,612 shares during the last quarter. Budros Ruhlin & Roe Inc. acquired a new stake in shares of Repligen during the first quarter valued at $220,000. Bayesian Capital Management LP acquired a new stake in shares of Repligen during the first quarter valued at $228,000. Profund Advisors LLC boosted its stake in shares of Repligen by 29.2% during the first quarter. Profund Advisors LLC now owns 7,174 shares of the biotechnology company’s stock valued at $260,000 after acquiring an additional 1,620 shares during the last quarter. Finally, Glen Harbor Capital Management LLC boosted its stake in shares of Repligen by 21.7% during the first quarter. Glen Harbor Capital Management LLC now owns 9,520 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 1,700 shares during the last quarter. 87.29% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply